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Abstract
Water soluble vitamins like Vitamin B3, B6 and B9 are of utmost importance
in human health and disease, as they are involved in numerous critical metabolic
reactions. Not surprisingly, deficiencies of these vitamins have been linked to various
disease states. For examples, Vitamin B6 deficiency has been related to many diseases
in humans especially in women with type 1 diabetes and in patients with systemic
inflammation, liver disease, rheumatoid arthritis, and those infected with HIV.
Similarly, derivatives of Vitamin B9 (such as folates), are needed to synthesize, repair,
and methylate DNA as well as to act as a cofactor in certain biological reactions. The
aim of this study was to develop a sensitive and robust HPLC/LC-MS/MS method for
the determination of blood levels of vitamins B6 and B3 from human plasma and to
apply it for the quantification of these vitamins in healthy and obese Emirati population
in the Al Ain region of UAE.
Keywords: Vitamins, obesity, Emirati population, bioanalytical quantification, serum.
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)Title and Abstract (in Arabic

التحليل الكروماتوجرافي لفيتامين ب 3وب 6ألشخاص أصحاء و بدناء في
المجتمع اإلماراتي بمدينه العين
الملخص
الفتامينات الذائبه في الماء مثل فيتامين ب ، 3فيتامين ب 6وفيتامين ب 9تعتبر من الفيتامينات
المهمه لصحه اإلنسان والوقايه من بعض األمراض ،ألنهم يدخلون في كثير من العمليات الحيويه
في جسم اإل نسان لذلك نقصهم أصبح مرتبط بأمراض كثيره ،ومثال علي ذلك فيتامين ب 6الذي
إرتبط نقصه بالسكري نوع أول في النساء ،وأمراض الكبد ،واإللتهابات الروماتيزميه ،ومرض
نقص المناعه (اإليدز) وكثير من اإللتهابات المزمنه.
و من األمثله علي ذلك أيضا فيتامين ب 9الذي إرتبط بأهميته في تخليق وإصالح الحمض النووي
وأيضا يعتبرعامل مساعد في العمليات الحيويه بالجسم لذلك نقصه يؤدي لخلل فيها.
و في هذه الدراسه كان هدفنا هوعمل طريقه تحليليه دقيقه وفعاله بإستخدام جهاز(الفصل
الكروماتوجرافي) يمكننا بها قياس مستوي فيتامين ب 3و ب 6في عينات دم خاصه بمجموعه من
أشخاص بدناء وأشخاص أصحاء من المجتمع اإلماراتي في مدينه العين بدوله اإلمارات العربيه
المتحدة.
مفاهيم البحث الرئيسية :الفيتامينات ،البدانة ،سكان اإلمارات ،تحليل بيولوجى ،بالزما الدم
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Chapter 1: Introduction
1.1 Historical background
Vitamins are a group of compounds that serve as co-factors for numerous
metabolic reactions functions in the cell. They form a cohesive group of organic
compounds that are required in human diet in small amounts (micrograms or
milligrams per day) to maintain various chemical and physiological functions in the
body [1]. Therefore, vitamins are distinguished from the essential inorganic minerals,
amino acids, and fatty acids, which are required in larger amounts [1]. Vitamins were
discovered at the beginning of the twentieth century by Hopkins [2], when he noticed
that a small amount of milk added to the diet of rats helped them in their growth as
compared with fats, proteins and carbohydrates. He concluded that one or more
essential growth factors are present in milk in small amounts, but were adequate to
maintain growth and development of the rats [2]. The first of these essential growth
factors was discovered in 1912 and was found to be amine in nature. Due to the fact
that it was realized as being important to life, it was called “vita amine”, or vitamin,
where vita means life in the Latin language, while amine was believed to be related to
ammonia in the Latin language [3]. Although next discovered essential growth factors
were not amines in nature, they are still grouped as vitamins.
Similar to most chemical compounds, vitamins are named after their chemical
structures. In addition, vitamins are also given names arising from the history of their
discovery. For several vitamins, a number of chemically related compounds show
similar biological activity, because they are either converted to the same final active
metabolite or have sufficient structural similarity to have the same activity. These are
collectively known as vitamers [4].
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For a compound to be considered a vitamin, it must be shown to be an essential
part of a regular diet, and that its deficiency must result in a clearly defined disease,
while restoration must cure or prevent that deficiency which causes a disease. In
addition, demonstrating that a compound has pharmacological actions, and possibly
cures a disease, does not classify that compound as a vitamin, even if it is a naturally
occurring compound that is found in foods. Moreover, demonstrating that a compound
has a physiological function as a coenzyme or hormone does not classify that
compound as a vitamin, and it is necessary to demonstrate that endogenous synthesis
of a vitamin is inadequate to meet the physiological requirements of the body, in the
absence of a dietary source of that compound.

1.2 Classification of vitamins
Vitamins are often classified based on their solubility into fat- or lipid-soluble
and water-soluble vitamins [1]. While the former includes vitamins A, D, E, and K.
The latter is composed of vitamin C and eight B-vitamins, namely thiamine (vitamin
B1), riboflavin (vitamin B2), niacin (vitamin B3), pyridoxine (vitamin B6),
pantothenic acid (vitamin B5), biotin (vitamin B7), folate (vitamin B9) and
cyanocobalamin (vitamin B12). Vitamin solubility factor, does not only decide their
distribution in various food groups, but it also plays an important part in their analysis
and quantification. Tables 1 and 2 show a list of fat- and water-soluble vitamins, their
common names, their chemical structures and their food sources [1]. The distinction
between fat- and water-soluble vitamins is solely based on the difference in chemical
structure of the vitamins, where fat-soluble vitamins are mainly hydrophobic or
lyophilic in nature. Water-soluble vitamins are hydrophilic in nature by virtue of the
polar groups, such as –OH, -NH2, and –COOH. Despite this classification, it should
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be noted that water-soluble derivatives of vitamins A, K, vitamin B fat-soluble
derivatives and vitamin C have been developed for therapeutic use and also as food
additives. Fat-soluble vitamins dissolve in fat before they are absorbed in the blood
stream to carry out their functions. Excessive amount of these vitamins are often stored
in the liver; as they are not needed every day in the diet. In contrast, water-soluble
vitamins dissolve in water and are not stored as they are often eliminated in urine.
Therefore, a continuous supply of these vitamins is needed in our daily diet.

1.3 Vitamins and food sources
Regular foods are often enriched with vitamins in stated amounts during their
processing. However, frequently manufacturers commonly add more than the stated
amount, which may cause health problems in certain cases. For example, recently a
debate arose in USA concerning folate enrichment of flour, because of the small
difference between the amount that is considered desirable and the amount that may
be hazardous, and the precision to which manufacturers can control the amount in the
final products [5]. Interestingly, the U.S. Pharmacopeia permits pharmaceutical
preparations to contain from 90% to 150% of the declared amount of water-soluble
vitamins and from 90% to 165% of the fat-soluble vitamins [1].
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Table 1: Names, chemical structure and sources of fat-soluble vitamins [6]
Name
Vitamin A

Common name
Retinol

Structure

Sources
Broccoli, Carrot,
Spinach, Apricot,
Tomatoes, Milk,
pumpkin
Egg yolk, Salmon, Tuna,
Sunflower seeds, Milk,
Sun

Vitamin D

Choleocalciferol
(Vitamin D3)

Vitamin E

-tocopherol

Wheat germ oil,
Almond, Kiwi, Broccoli,
Mango , Avocados

Vitamin K

Phylloquinone
(Vitamin K1)

Spinach, Lettuce,
Avocado, Asparagus,
Parsley
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Table 2: Names, chemical structure and sources of water-soluble vitamins [7]
Name
Vitamin C

Common name
Ascorbic acid

Structure

Sources
Red pepper, Kiwi,
Broccoli, Spinach,
Grapefruit, Avocado,
orange, Banana
Legumes, Rice, Corn
flour, Spinach

Vitamin B1

Thiamine

Vitamin B2

Riboflavin

Milk,
Cheese, Eggs, leafy
vegetables, liver,
Mushrooms, Almond

Vitamin B3

Niacin

Vitamin B5

Pantothenic
acid

Sesame seed, Ginger,
Green sweet pepper,
baked Potato
Dried Mushrooms,
Liver, dried Egg yolks,
Sunflower seeds

Vitamin B6

Pyridoxine

Banana, Watermelons,
brown Rice, Salmon,
Tuna, Chicken

Vitamin B7

Biotin

Egg, Pecans, Penuts,
Green peas, Butter

Vitamin B9

Folic acid

Leafy vegetables,
Avocado, Beetroot,
Spinach, Liver, Yeast

Vitamin B12

Cobalamin

Clams, Lamb liver, Fish
eggs, Crab meat
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It should be mentioned that concentrations of vitamins in the body are strongly
linked to their intake in the daily regular meals. Most of the vitamins are absorbed by
active transport, therefore, the percentage that is absorbed will decrease as the intake
increases. Fat-soluble vitamins (A, D, E, and K) are absorbed in lipid micelles, and,
therefore, absorption will be impaired when the meal is low in fat. Gastrointestinal
pathology that results in impaired fat absorption will also impair the absorption of fatsoluble vitamins, because they remain dissolved in the unabsorbed lipid in the
intestinal lumen [8]. Lipase inhibitors used for the treatment of obesity and fat
replacers (e.g., sucrose polyesters such as OlestraTM) will similarly impair the
absorption of fat-soluble vitamins. On the other hand, many of the water-soluble
vitamins are present in foods bound to proteins, and their release may require either
the action of gastric acid (as for vitamin B12) or specific enzymatic hydrolysis [e.g.,
the action of conjugase to hydrolyze folate conjugates and the hydrolysis of biocytin
to release biotin. In addition to the above, the state of body reserves of the vitamin may
affect the extent to which it is absorbed (by affecting the synthesis of binding and
transport proteins) or the extent to which it is metabolized after uptake into the
intestinal mucosa. There are also compounds naturally present in foods that may have
antivitamin activity [8]. For example, certain foods contain thiaminases and
compounds that catalyze nonenzymic cleavage of thiamine to biologically inactive
products. Moreover, drugs and compounds that are naturally present in foods may
compete with vitamins for absorption. For example, chlorpromazine, tricyclic
antidepressants, and a number of antimalarial drugs inhibit the intestinal transport and
metabolism of riboflavin; carotenoids lacking vitamin A activity compete with βcarotene for intestinal absorption and metabolism; and alcohol inhibits the active
transport of thiamine across the intestinal mucosa [8].
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A number of vitamins are present in foods in chemical forms that are not
readily available for absorption in the body. For example, much of the vitamin B6 in
plant foods is present as pyridoxine glycosides, which are only partially bioavailable,
and may also antagonize the metabolism of free pyridoxine [9]; excessive heating can
lead to nonenzymic formation of pyridoxyllysine in foods, rendering both the vitamin
and the lysine unavailable. Similarly, most of the niacin in cereals is present as niacytin
(nicotinoyl-glucose esters in oligosaccharides and non-starch polysaccharides), which
is only hydrolyzed to a limited extent by gastric acid. Moreover, protein binding of a
vitamin on foods increases its absorption and hence its biological availability. For
example, folate from milk is considerably better absorbed than that from either mixed
food folates or free folic acid. Folate bound to a specific binding protein in milk is
absorbed in the ileum, whereas free folate monoglutamate is absorbed in the (smaller)
jejunum.

1.4 Water-soluble vitamins
Water-soluble vitamins readily dissolve in water and are not stored as they are
eliminated in urine. Therefore, a continuous supply of them is needed in our diets. The
water-soluble vitamins can be divided into the B-complex group and vitamin C. Watersoluble vitamins are easily destroyed or washed out during food storage or preparation.
However, proper storage and preparation can minimize their loss. Eight different
water-soluble vitamins make up the B-complex group: thiamine (vitamin B1),
riboflavin (vitamin B2), niacin, vitamin B6, folate, vitamin B12, biotin and pantothenic
acid. These vitamins are widely distributed in foods. Their influence is felt in many
parts of the body. They function as coenzymes that help the body obtain energy from
food. They also are important for normal appetite, good vision, healthy skin, healthy
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nervous system and red blood cell formation. Beriberi, pellagra and pernicious anemia
are three well-known B-vitamin deficiencies [10]. These diseases are not a problem in
the United States, but occasionally they occur when people omit certain foods or
overeat certain foods at the expense of others. Alcoholics are especially prone to
thiamin deficiency because alcohol replaces food. Vegans will need a B12 supplement.
When grains and grain products are refined, essential nutrients lost during
processing are put back into these foods through a process called enrichment. Among
the nutrients added during the enrichment process are thiamin, niacin, riboflavin, folate
and iron. Some examples of enriched grain products are white rice, many breakfast
cereals, white flour, breads and pasta. For some populations, rice is the main dietary
staple. When “polishing” rice (removing its outer layers) became popular, thiamin
deficiency, or beriberi, increased significantly [10].
In the early 1900s, the most widespread vitamin deficiency disease in the
United States was pellagra, or niacin deficiency. At that time, pellagra caused
thousands of deaths and many cases of mental and physical illness among the poor in
the Southeast. The enrichment of flour, rice and wheat products helped to eliminate
the deficiency problems found in people who depended on these food items for most
of their daily calories. Table 3 shows the source, major functions, deficiency
symptoms, the over consumption symptoms and the stability in foods of water-soluble
vitamins [11].
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Table 3: Water-soluble vitamins and their characteristics [11]
Vitamins

Best sources

B-1
(Thiamin)

Whole wheat
products, pork,
liver, and peas
B-2
Meats, fish,
(Riboflavin) whole grains,
dairy products,
vegetables,
legumes
Niacin
Whole grains,
dairy products,
liver
B-6

Meats, fish, nuts,
whole grains,
fruits,
vegetables,
legumes

Folate
(also known
as: F, B9,
Folic Acid,
or Folacin)

Liver, kidney,
dark green leafy
vegetables,
fruits, peas, and
beans

B-12

Liver, kidney,
red meats, dairy
products, eggs,
fish

Pantothenic
Acid

Liver, kidney,
yeast, egg yolks,
peanuts, whole
grains, beef,
skim milk,
potato, tomato
Liver, kidney,
egg yolks, milk,
yeast
Fruits (especially
citrus) and
vegetables

Biotin

C
(Ascorbic
Acid)

Function

Deficiency
Symptoms

Daily
Amount

Helps convert
carbohydrates to
energy
Aids many enzyme
reactions that
convert food into
energy

Loss of energy,
nerve damage,
muscle weakness
Dry, scaly skin,
cracks on lips and
corners of mouth,
light sensitivity

12.5 mg,
2x daily

Aids many enzyme
reactions that
convert food into
energy
Helps convert
protein’s amino
acids into energy,
Synthesizes: amino
acids, muscle
proteins,
hemoglobin, insulin,
and immune proteins
Required for DNA
metabolism,
important for genetic
functions such as
cell division and
growth
Required for DNA
metabolism, red
blood cell formation,
maintains central
nervous system
Helps convert fatty
acids into energy.
Synthesis of fatty
acids, cholesterol,
hormones

Mental impairment,
delirium, diarrhea,
swelling of mouth

15 mg,
2x daily

Depression, loss of
energy, loss of
appetite, nausea,
vomiting, swelling
of mouth and tongue

2 mg,
2x daily

Anemia, swelling of
tongue, diarrhea. In
pregnancy, anemia,
miscarriage, and
birth defects

200 mcg,
2x daily

Anemia,
degenerative
changes in the
nervous system

400 mcg,
2x daily

No appetite, nausea,
indigestion, moods,
cramps, depressed
immune system,
rapid pulse, fainting

150 mg,
2x daily

Helps digest
carbohydrates and
make fatty acids
Aids in wound
healing, improves
immune system,
helps make amino
acids, helps iron
absorption

No appetite, anemia,
scaly skin, weight
loss, hair loss
Anemia, depressed
immune system,
bruising, weakened
bones and cartilage,
muscle degeneration

150 mcg,
2x daily

12.5 mg,
2x daily

250 mg,
2x daily
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Vitamin B referred to a vitamin whose deficiency causes beriberi in man and
polyneuritis in birds. Later, Goldberger’s researches on pellagra led to the view that
vitamin B consisted of at least 2 factors: a heat-labile antiberiberi factor and a
comparatively heat-stable antipellagra factor. Some called the former factor as
vitamin B1 and the latter as vitamin B2. But the later researches conducted by Richard
Kuhn, Conrad Elvehjem and others have established the fact that vitamin B complex,
as represented by yeast, rice bran and liver extracts, contains still other factors. At
present, the vitamin B complex is known to consist of a group of at least 13
components usually named as B1, B2, B3 etc. But to prevent confusion, their chemical
names are now frequently used [12]. The various members of the vitamin B complex
are not related either chemically or physiologically, yet they have many features in
common:
(a) All of them are water-soluble.
(b) Most of them, if not all, are components of coenzymes that play vital roles
in metabolism (Table 4). Table 5 demonstrates the coenzyme reactions that B
vitamins are involved in.
(c) Most of these can be obtained from the same source, i.e., liver and yeast.
(d) Most of them can be synthesized by the intestinal bacteria.
Several water soluble vitamin metabolites are involved in cellular metabolism,
mainly as coenzymes, to prevent metabolic disorders. Most of them are essential for
energy metabolism. The phosphorylated forms of thiamine (Vit.B1) play a key role in
the Krebs cycle [13,14]. Riboflavin (Vit.B2), niacin (Vit.B3), pantothenic acid
(Vit.B5),

pyridoxal

5-phosphate

(circulating

form

of

Vit.B6),

5-methyl

tetrahydrofolate (circulating form of Vit.B9) and biotin (Vit.B8) are involved in
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oxidation/reduction reactions, fatty acid and neurotransmitters synthesis or one carbon
metabolism [15-18].
Because all these vitamers are directly involved in various body functions, their
deficiency will impact human health. Supplementation is therefore highly
recommended for targeted populations such as pregnant women, lactating women,
infants, elderly and athletes to either prevent diseases and/or risks such as
cardiovascular risk [19], anemia, cognitive impairment [20], or neural tube defect
[21,22]. Supplementation also improves physical performance of the same targeted
population [23].
Vit.B6 has been shown to be important for normal cognitive function and in
lowering the incidence of coronary heart disease among the elderly [24-26]. In
addition, Vit.B6 supplementation has been shown to reduce diabetic complications and
the incidences of neurodegenerative diseases in varying degrees [27]. Vit. B-6 includes
pyridoxal, pyridoxine, and pyridoxamine, their intracellular conversion is shown in
Figure 1, which function as essential cofactors for enzymes involved in various
metabolic activities, which include amino acid, fat, and glucose metabolism [28]. The
phosphate ester derivative pyridoxal 5’-phosphate (PLP) is the biologically active
form of this vitamin [29] and reflects long-term body storage [30]. Figure 1 shows the
intracellular conversion of vitamin B6 vitamers in the human body [31]. Studies have
shown that low plasma PLP concentrations are associated with increased risk of
cardiovascular disease (CVD) [32,33].
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Table 4: Coenzyme derivatives of B vitamins [12]
Vitamin

Coenzyme form

Vitamin B1 (Thiamine)

Thiamine pyrophosphate (TPP)

Vitamin B2 (Riboflavin)

Flavin mononucleotide (FMN)
Flavin adenine dinucleotide (FAD)

Vitamin B3 (Niacin)

Coenzyme A (CoA)

Vitamin B5 (Pantothenic acid)

Nicotinamide adenine dinucleotide (NAD)
Nicotinamide adenine dinucleotide phosphate
(NADP)

Vitamin B6 (Pyridoxine)

Pyridoxal phosphate (PALP), Pyriodoxamine
phosphate (PAMP)

Vitamin B7 (Biotin)

Biocytin

Vitamin B9 (Folic acid)

Tetrahydrofolic acid (THFA)

Vitamin B12 (Cyanocobalamin)

Deoxyadenosyl cobalamin
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Table 5: Coenzyme reactions and consequences of deficiency that B vitamins
are involved in
Vitamin

Coenzyme

Typical reaction
type

Consequences of deficiency

Thiamin (B1)

Thiamine
pyrophosphate

Aldehyde transfer

Beriberi (weight loss, heart
problems, neurological
dysfunction)

Riboflavin (B2)

Flavin adenine
dinucleotide
(FAD)

Oxidation-reduction

Cheliosis and angular stomatitis
(lesions of the mouth), dermatitis

Pyridoxine (B6)

Pyridoxal
phosphate

Group transfer to or
from amino acids

Depression, confusion,
convulsions

Nicotinic acid
(Niacin)

Nicotinamide
adenine
dinucleotide
(NAD+)

Oxidation-reduction

Pellagra (dermatitis, depression,
diarrhea)

Pantothenic
acid

Coenzyme A

Acyl-group transfer

Hypertension

Biotin

Biotin-lysine
adducts (biocytin)

ATP-dependent
carboxylation and
carboxyl-group
transfer

Rash about the eyebrows, muscle
pain, fatigue (rare)

Folic acid

Tetrahydrofolate

Transfer of onecarbon components;
thymine synthesis

Anemia, neural-tube defects in
development

B12

5’-Deoxyadenosyl
cobalamin

Transfer of methyl
groups;
intramolecular
rearrangements

Anemia, pernicious anemia,
methylmalonic acidosis
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Recent data have shown that plasma PLP was adversely associated with
inflammatory markers, which include C-reactive protein (CRP), fibrinogen, and blood
cell count [33-36] Additionally, low vitamin B-6 concentrations are commonly present
in diseases with a strong inflammatory basis, such as diabetes [37], rheumatoid arthritis
[38], and inflammatory bowel disease [39]. Current evidence highlights the notion that
inflammation may represent another link between vitamin B-6 and CVD. However,
the relation of vitamin B-6 status with inflammation and other CVD risk factors has
not been investigated extensively in a population at high risk of CVD [40].
Niacin, also known as vitamin B3 (Vit. B3), is an endogenous molecule having
medicinal role. It is a precursor of coenzymes nicotinamide adenine dinucleotide
(NAD) and nicotinamide adenine dinucleotide phosphate (NADP). These coenzymes
trigger dehydrogenase reactions and have catalytic impact of many biomolecules [41].
Figure 2 shows the intracellular conversion of Vit B3 vitamers into NAD+ coenzyme.
Niacin basically decreases low density lipoprotein cholesterol (LDL), very lowdensity lipoprotein cholesterol (VLDL-C), and triglycerides (TG), but effectively
increases high density lipoprotein cholesterol (HDL) [42]. Niacin alone [43] or in
combination with other lipid lowering agents such as statin [44] or ezetimibe [45]
significantly reduces risk of cardiovascular disease and arthrosclerosis progression
[46] or hardening of the arteries. It lowers the risk of heart attacks. There is also some
evidence that it might help in lowering the risk of Alzheimer's disease, cataracts,
osteoarthritis, and type 1 diabetes [47]. On the other hand, type 2 diabetes is often
attributed to an unhealthy lifestyle.
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Figure 1: The different vitamin B6 vitamers and their intracellular conversions [31]
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Figure 2: The different vitamin B3 vitamers and their intracellular conversions [1]
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The current recommendation for the prevention and management of type 2 diabetes is
a healthy, balanced diet, with particular focus on maintaining a healthy weight and
physical activity [48]. Therefore, the benefit of isolated vitamins and their role in the
prevention and treatment of type 2 diabetes continues to be a focus for research.
According to the British National Formulary (BNF), nicotinic acid can be used in doses
1.5–3 g daily to lower cholesterol and triglycerides by inhibiting synthesis, while
raising high-density lipoprotein cholesterol [49]. It is often used in combination with
a statin. A small number of studies have shown the beneficial effects of niacin on CV
events in people with type 2 diabetes.
Obesity is a risk factor for type 2 diabetes, cardiovascular diseases, cancer,
pulmonary diseases, osteoporosis, periodontal diseases and has consequences on lipid,
glucose and protein metabolism [50]. Obesity is a chronic disease of multifactorial
origin that develops from the interaction of social, behavioral, psychological,
metabolic, cellular, and molecular factors [51]. It is the condition under which adipose
tissue is increased and can be defined as an increase in body weight that results in
excessive fat accumulation. The World Health Organization (WHO) defines obesity
as a body mass index (BMI) > 30 and defines overweight as with a BMI of 25 [52].
Adipose tissue is not only a triglyceride storage organ, but studies have shown
the role of white adipose tissue as a producer of certain bioactive substances called
adipokines. These adipokines induce the production of reactive oxygen species (ROS),
generating a process known as oxidative stress (OS) [53]. The levels of inflammatory
and oxidative stress markers were highly prevalent among overweight/obese Emirati
women and this may predispose to increasing cardiovascular risks at relatively young
age [54]. Therefore, the unbalanced diet that doesn’t provide the recommended daily
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intake of vitamins and minerals can lead to health problems so we need a better
promotion for lifestyle changes, both in normal weight and obese subjects [50].
Most published work on Vit.B6 is limited to general clinical observations and
case studies. Although the role of Vit.B6 in reducing the complications associated with
diabetes, aging, and neurodegenerative diseases has been widely reported [24,25,5556]. Based on the above, the current study investigates the levels of vitamins B3 and
B6 in healthy and obese Emirati population in an attempt to correlate the levels of
these vitamins with obesity.
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1.5 Analysis of B vitamins and related biochemical compounds
It is still well accepted and appreciated that accurate biochemical assessment
will allow for more specific diagnosis. There is an obvious advantage in being able to
detect biochemical signs of early or marginal deficiency. An individual who shows
biochemical evidence of deficiency or inadequacy may be metabolically stable, and
adequately adapted to his or her current intake, or maybe in the early stages of
developing clinically significant deficiency disease. In population studies, whereas the
number of people with clear clinical deficiency signs gives some indication of the scale
of the problem, detection of the larger number who show biochemical signs of
deficiency gives a better indication of the number of people at risk of developing
deficiency, and hence a more realistic estimate of the true scale of the problem.
Biochemical criteria of vitamin adequacy and methods for biochemical
assessment of nutritional status can be divided into the following two distinct groups:
1. The determination of the concentration vitamins and their metabolites in
human plasma, urine, or tissue depends on the comparison of an
individual/group with the population reference range, which is normally taken
as the 95% confidence interval: twice the standard deviation about the mean
value. By definition, 5% of the normal healthy population will lie outside the
95% reference range.
2. Metabolic loading tests and the determination of enzyme saturation with the
cofactors measure the ability of an individual to meet his or her idiosyncratic
requirements from a given intake, and, therefore, give a nearly absolute
indication of nutritional status, without the need to refer to population reference
ranges. A number of factors other than vitamin intake or adequacy can affect
responses to metabolic loading tests. This is a particular problem with the
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tryptophan load test for vitamin B6 nutritional status; a number of drugs can
have metabolic effects that resemble those seen in vitamin deficiency or
depletion, it is not known whether or not they could cause functional
deficiency.
The determination of water-soluble vitamins in various samples is rather
difficult due to the chemical instability and complexity of the matrices in which they
usually exist. As their chemical structures are not related, a considerable number of
publications have appeared using different physical, chemical and biological methods
to quantify them [57]. Most of the available analytical methods are time-consuming or
not accurate. These techniques are based on the spectrophotometric, fluorimetric,
enzymatic or microbiological properties of these vitamins assay techniques [57].
Capillary electrophoresis (CE) is one of the most popular chromatographic
technique [58-61] along with high performance liquid chromatography (HPLC). These
techniques are rapid, sensitive, accurate and have proven to be more effective for
measurements of water-soluble vitamins concentration in pharmaceutical formulations
[61-67]. The application of HPLC coupled with detectors ultraviolet/visible [61-65,
67-73], fluorimetric [74-75] or electrochemical [76-80] are already available in in the
literature. Critical factor for the development of HPLC methods is always the selection
of the appropriate column and column packing material [81-85]. Most of the published
methods are based on the gradient techniques [86-87], which can be very sensitive to
pH changes of the mobile phase.
Validated analytical methods for vitamin determination in pharmaceutical
preparations such as tablets, capsules and oral solutions are mostly HPLC-based but
individual methods for each different vitamin are also proposed [61]. Recently, a
number of methods for the simultaneous determination of water-soluble vitamins have
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been reported [72, 87-93], but the stability studies were not reported in details. Some
of the HPLC methods have been used for the determination of vitamin-related
compounds like thiamine and related compounds [68] as well as pyridoxine vitamers
[94]. HPLC method for separation of pyridoxine vitamers, pyridoxic acid and its
degradation product in plasma has also been published [95].
Depending on the compound of interest, some analytical standards have been
well established years ago and are widely applied to quantify them in food and human
blood samples. Microbiological methods have been traditionally used and, although
this is currently changing, though they are still part of reference standards used for
food control in different parts of the world [96-97]. Although these types of assays for
vitamin analysis have been applied to the analysis of human serum or plasma, they
present the disadvantage of providing an enormous result, without the possibility of
differentiating between native vitamin used in food supplementation and its
metabolites, which limits its application in clinical analysis. Other techniques are also
applied for the analysis of food, such as the enzyme-linked immunosorbent assay
(ELISA) [98], radio immunoassay (RIA) [99], protein-binding or biosensor based
[100-102] with the same disadvantage on the differentiation of metabolites.
Fluorescence detection combined with liquid chromatography has been extensively
used to quantify B1 [103], B2 [104], B6 [105-106] and biotin [64] in foods and
biological fluids but also used to validate multi-analyte methods in food matrices. For
example, Heudi et al. reported a single chromatography for the quantification of 8
water soluble vitamins used for fortification in premixes samples [107]. In the past ten
years, liquid chromatography hyphenated with tandem mass spectrometry (LCMS/MS) has been demonstrated to be a more and more attractive technique with
various advantages such as improved sensitivity and higher resolution for the analysis
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of water soluble vitamins. The vitamins used for fortification and/or their naturally
present vitamers are then quantified individually [108-109] or in multi-analyte
methods [110-115]. Only few methods have been published for the analysis of water
soluble vitamins in biological fluids such as human milk [105, 116], human plasma
[104] or urine [117], where a single vitamin was quantified. More recent studies
demonstrated the trend to go further into multianalyte methodologies [117]. For
instance, in 2012, Hampel et al. quantified four different water soluble vitamins
represented by five analytes in human milk by LC-MS/MS [118]. So far, an analytical
approach for performing the simultaneous quantification of B1, B2, B3, B5, B6, B8
and B9 and their main circulating forms in human plasma has not been published. This
can be of a great advantage when vitamer profiling is required in large longitudinal
studies [119].
High variability of vitamin B6 forms and their low concentration in human
matrices cause difficulties in their accurate analysis [120]. Vitamin B6 status is
typically assessed by measuring the level of one or more of the B6 vitamers in serum
or plasma. Serum PLP is generally viewed as the best single indicator of B6 status.
Serum or urinary 4-pyridoxic acid, the end product of vitamin B6 catabolism, is an
indicator of recent intake. Vitamin B6 data are usually presented in the form of serum
PLP and 4-pyridoxic acid, as generated by use of HPLC with post-column
derivatization and fluorometric detection [121]. A cutoff value of 20 nmol/L is used to
indicate low serum PLP concentrations. This cutoff value was used by the Institute of
Medicine as the basis for the Estimated Average Requirement (EAR); however, it may
overestimate the vitamin B6 requirement for health maintenance of more than half the
group.
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The biochemical assessment is usually conducted by means of chemical
analysis of the vitamers, their metabolites and/or functional tests. Analytical
techniques include determination of PLP in plasma and red cells. PLP metabolite, e.g.
4-pyridoxic acid can be measured in urine or plasma, as well as the activity and
activation coefficient with the red cell aminotransferases, and the tryptophan load
metabolite test [122-123]. Combination of these markers provides a reliable approach
for practical laboratory methods. Consequently, the use of microbiological [124-125],
enzymatic and radio-enzymatic [126-129], spectrofluorometric [130] and liquid
chromatographic methods [131] has been reported for this purpose.
The majority of separation procedures is achieved by the use of reversed-phase
high-performance liquid chromatography (HPLC) coupled with fluorescent [132] and
UV [133] detections. Corbun and Mahuren [134] reported a cation-exchange HPLC
procedure, involving a gradient elution and a post-column bisulfide derivatization
followed by fluorescence detection that was suitable for quantifying B6 components
in human plasma. Some other methods have been also used to enhance the
fluorescence of PL and PLP by bisulfide adduct formation [135], formation of
semicarbazones by reaction with semicarbazide [136], and oxidation by cyanide to
carboxylic acid [137-139]. Modified fluorescent methods eliminated cyanide by postcolumn conversion of PLP to 4-pyridoxic acid and 5-phosphate by chlorite [140].
Midttun et al. [141] reported the potential of liquid chromatography combined with
tandem mass spectrometry (LC–MS) for the quantification of all known forms of
vitamin B6 and riboflavin in human plasma. There were also other successfully
validated methods of vitamin B6 detection based on a redox reaction with
electrochemical detectors, i.e. amperometric or coulometric detectors. The oxidation
of PN at a carbon paste electrode has been firstly examined. Consequently,
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modification of the glassy carbon electrodes, flow and sequential injection techniques
improved speed and selectivity as compared with electrochemical assays [79]. The
chemical structure of all the particular vitamin B6 forms enables their measurement
by electrochemical detection at nanomolar concentrations in endogenous plasma and
serum. It should be mentioned that use of electrochemical detection has been already
reported in literature [57]. However, such application was limited to samples other
than pharmaceuticals and foods.
Accurate determination of all forms of vitamin B6 is essential for assessing
nutritional and metabolic requirements and the metabolism of this vitamin. However,
the task of measuring these forms becomes quite difficult because of the complexity
of the biological matrix and the extremely low concentration of these compounds in
plasma (nanomoles per liter or less) [142]. A number of methods have been developed
for the assay of B6 vitamers in plasma for clinical and nutritional purposes. These
include microbiological, enzymatic, or chemical methods and more recently high
performance liquid chromatography (HPLC) [143].
Vitamin B6 forms in serum are most commonly measured by high performance
liquid chromatography (HPLC) with fluorometric detection; chemical derivatization
(sample, online, or post-column) is almost always used to enhance PLP fluorescence
[121]. Enzymatic (radioactive or nonradioactive) and microbiological methods have
also been employed [141]. The comparability of methods could be improved [144];
such improvement is expected to occur in the future due to the new availability of
NIST SRM 1950 and 3950 (certified concentrations for serum PLP by LC-MS/MS).
Today HPLC procedures with appropriate detection systems are regarded as the most
convenient method for the evaluation of vitamin B6 nutritional status. Several HPLC
procedures for the assay of B6 vitamers have been reported; however, most suffer from
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inadequate resolution and lack of sensitivity [144-147]. Furthermore, it is difficult to
adopt some of these methods in the routine setup because of the unavailability of
columns used [148]. It is also important to note that except very few studies [148],
little attention has been paid for the accuracy and imprecision of the assays.
Clinical analysis of vitamin B6 is accomplished at present by a variety of
enzymatic assays and HPLC methods [149]. Although some direct comparisons of
these methods can be found in the literature (usually in the form of comparing results
from a new method with an established one as a part of method validation), objective
comparative studies of vitamin B6 measurements among several methods or
laboratories are rare. The only previously published account of a multi-laboratory
comparative study of vitamin B6 measurements in human biological specimens was
conducted by Reynolds in 1983 [150], in which a single pooled plasma sample was
sent to 14 US laboratories routinely performing B6 analyses. Results from this study
showed a wide range of values for the B6 vitamer and metabolite content of the
specimen. For pyridoxal 5-phosphate (PLP), the primary circulatory form of vitamin
B6, six different laboratories using enzymatic methods reported concentrations of 53–
65 nmol/L for the specimen; the remaining laboratories, using HPLC, found PLP
concentrations of 48–1700 nmol/L.
The biggest advantage of an LC–MS/MS method is the simple work up, only
protein precipitation under acidic conditions is needed before the sample could be
injected. This is in sharp contrast to HPLC methods, where derivatization of both
molecules is required because of the lack of a fluorophore in their chemical structures
[151]. However, it is still challenging to transfer an existing LC–MS/MS method to
another system without additional optimization. The choice of column, mobile phase,
gradient and MS-settings are very delicate matters and often it comes down to
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redeveloping the method for the new setup [152]. Furthermore, every laboratory has
its own routines and preferences, mostly dictated by other tests that are run on the same
MS/MS system.

1.6 Aim of the study
Based on the above, the main objectives of the current work are to:
1. Develop a sensitive robust and easy LC-MS/MS based assay for measuring
vitamins B6 and B3 in human plasma.
2. Use the above method to measure plasma vitamins B6 and B3 in healthy and
obese Emirati population.
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Chapter 2: Materials and Methods
2.1 Materials
Vitamin standards and other reagents were purchased from different suppliers:
Pyridoxal -5’- phosphate hydrate, Pyridoxal hydrochloride, Pyridoxamine -5’-phosphate,
Nicotinamide,

Phosphate

buffered

saline,

Tris(2-carboxyethyle)phosphate

hydrochloride, Heptafluorobutyric acid, Trichloroacetic acid, Formic acid, and LC-MSgrade water were purchased from Sigma-Aldrich, USA. Pyridoxine hydrochloride was
purchased from Supelco and Pyridoxamine dihydrochloride was purchased from Fluka,
USA. While HPLC-grade acetonitrile was purchased from Merck, USA.

2.2 Methods
2.2.1 Preparation of standard solutions
Stock individual solutions of all B6 vitamers, B3 and internal standards were
prepared at 1000 ppm (1µg/ml) in deionized water. These stock solutions were kept in
Eppendorf tubes and stored at -80℃ to avoid degradation. Working solutions of
vitamins standards were prepared daily by mixing and diluting individual stock
solutions in DI water to desired concentrations. Preparation steps were protected from
light during laboratory handling by using amber tubes to prevent vitamins from
degradation.

2.2.2 Plasma sample extraction method
Plasma samples from the test subjects were stored at -80℃, were thawed right
before the analysis. An aliquot of 300 l was taken into an Eppendorf tube and spiked
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with 10 l of the internal standard (100 ppm) then the mixture was vortexed for 2
minutes. The proteins were precipitated by adding an equal volume of 0.6 N TCA to
produce a final TCA concentration of 0.3 N. The samples were vortexed for 2 minutes
and then incubated for 5 minutes at 50℃. The samples were then centrifuged at 11,000
rpm for 10 minutes at 4℃. The resulting supernatant was filtered using CA filter
(0.22m) then transferred into HPLC amber vials and placed in an autosampler where
the samples were kept at 4℃ and protected from light. Normally, 8 l of sample extract
was injected into LC-MS/MS system.

2.2.3 Liquid chromatography and mass spectrometry
LC separation of vitamins was achieved with Agilent 1260 HPLC-system on a
reversed-phase column Poroshell 120 EC-C18 (Agilent Technology, Santa Clara, CA,
USA) with a particle size 2.7 m, an inner diameter of 3.0 mm and a length of 100
mm. The column was maintained at 35oC and a constant flow rate of 0.4 ml/min. Two
mobile phases were used: A was LC-MS grade water containing 0.1% Formic acid and
0.1% Heptafluorobutyric acid, and B, which was Acetonitrile containing 0.1% Formic
acid. The LC method was set as follow: 3 min of 100% A, followed by a 0-100%
gradient of B from 3-5 min, then 100% of B from 5-8:50 min and ended with 100% A
from 8:60 - 10 min, followed by 100% A for 5 min as post run. Mass spectrometry
analysis was performed on an Agilent 6420 Triple Quadrupole MS system in positive
electrospray ionization (ESI+) mode. Electrospray voltage was set at 4 kV, Ion source
gas 1 (desolvation gas consisting of nitrogen 99.9%) pressure was set at 20 psi, ion
source gas 2 (nebulizer gas consisting of nitrogen) was set at 45 psi and the drying gas
(N2) flow was 8 L/min at 325℃. Table 6 shows the precursor and product ions along
with their collision energies.
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Table 6: Shows names, structure, mass, precursor and product ions along with
collision energies

Name

Vitamer Structure

Pyridoxal-5'phosphate
(PLP)

Precursor
ion
(m/z)
248

Product
ion
(m/z)
149.7

Collision
energy
(eV)
15

203.63
167.06
(-HCl)

168

149.9

10

241.11
168.09
(-2HCl)

169

152

10

248

249

232.1

10

205.64
169.07
(-HCl)

170

151.9

122.12

123

80.2

20

208.6

173

155

10

Mass
(g/mol)
247

C8H10NO6P

Pyridoxal
hydrochloride
(PL)
C8H9NO3 · HCl

Pyridoxamine
dihydrochloride
(PM)
C8H12N2O2 · 2HCl

Pyridoxamine-5'phosphate
(PMP)
C8H13N2O5P

Pyridoxine
hydrochloride
(PN)

10

C8H11NO3 · HCl

Nicotinamide
C6H6N2O

Pyridoxine(methyl-d3)
hydrochloride
C8D3H8NO3·HCl
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Chapter 3: Results and Discussion
3.1 Development of LC-MS/MS-based method
An extraction approach for vitamins B6 and B3 was developed after trying
many extraction techniques along with developing a sensitive and robust LC-MS/MS
method for analysis of these metabolites.
In the following sections, the sequence of the experiments that have been carried
out in this regard will be discussed. It started with the identification of product ions
of each precursor ions of each analyte. This was followed by checking the effect of
varying the multiplier voltage (Delta EMV) on the intensity of the peaks produced.
Then, the effect of changing the types of columns on the resolutions of the obtained
peaks was also investigated. During experimental procedure, the selected incubation
conditions were tested in order to improve the yield of our analytes. In addition to the
above, the reproducibility of our method were also tried and tested along with testing
the recovery of all analytes.
Based on the detailed study of the above mentioned parameters an optimization
of the method was reached and evaluated.

3.2 Multiple reaction monitoring (MRM) (precursors and product ions
identification)
Compounds with different structures respond differently to the fragmentor
setting. The ideal fragmentation voltage for each component was detected through the
injection of individual standards. The fragmentor was set up in positive mode. Based
on the mass of the standards under different collision energies, daughter ions were
detected. The following components were found to be matching those found in the
literature: Nicotinamide, pyridoxamine (PM), pyridoxamine 5-phosphate (PMP)
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[119], and pyridoxal 5-phosphate (PLP) [153]. Other vitamers including, pyridoxal
(PL) and pyridoxine (PN) were found to be close to the values found in the literatures
[119].
The following Figures illustrate the Electrospray ionization (ESI) product ions,
at different collision energies (CE), of each analytes. In Figures 3a, b and c of PLP
shows that the precursor ion m/z (248) was not fragmented properly but in 3d the
fragmentation was occurred and product ion m/z (149.7) signal was high intensity at
collision energy eV (15). In Figure 4c of PL, the precursor ion m/z (168) was totally
fragmented and gave a very intensive peak m/z (149.9) at collision energy eV (10).
Figure 5b shows the precursor ion m/z (232.1) of PMP is clearly detected at collision
energy eV (10). In Figure 6b, the intensity of product ion m/z (152) of PM m/z (169)
was obtained at collision energy eV (10). In Figure 7(d), the product ion of PN m/z
(151.9) was the strongest one at collision energy eV (10). For Nicotinamide precursor
ion m/z (123), the high intensity product ion was m/z (80.2) which is detected at
collision energy eV (20) at which the precursor ion is totally fragmented shown in
Figure 8d. The daughter ions of the internal standard PN-d3 m/z (173) in Figure 9d
was detected at collision energy eV (10). The precursor and product ions as well as
the fragmentor voltage and collision energies values determined for the various
analytes are summarized in Table 7.
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Figure 3: ESI Fragmentation of PLP of different collision energy (CE), Asterisk (*)
refers to the precursor ion, followed by a schematic showing the fragmentation of
the PLP molecule and the structure of the precursor and daughter ions
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Figure 4: Fragmentation of PL of different collision energy (CE),
Asterisk (*) refers to the precursor ion, followed by a schematic showing the
fragmentation of the PL molecule and the structure of the precursor and daughter ions
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Figure 5: ESI Fragmentation of PMP of different collision energy (CE),
Asterisk (*) refers to the precursor ion, followed by a schematic showing the
fragmentation of the PMP molecule and the structure of the precursor and
daughter ions
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Figure 6: ESI Fragmentation of PM of different collision energy (CE),
Asterisk (*) refers to the precursor ion, followed by a schematic showing the
fragmentation of the PM molecule and the structure of the precursor and
daughter ions
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Figure 7: ESI Fragmentation of PN of different collision energy (CE), Asterisk
(*) refers to the precursor ion, followed by a schematic showing the
fragmentation of the PN molecule and the structure of the precursor and
daughter ions
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Figure 8: ESI Fragmentation of Nicotinamide of different collision energy
(CE), Asterisk (*) refers to the precursor ion, followed by a schematic showing
the fragmentation of the Nicotinamide molecule and the structure of the
precursor and daughter ions
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Figure 9: ESI Fragmentation of PN-d3 of different collision energy (CE), Asterisk
(*) refers to the precursor ion, followed by a schematic showing the fragmentation
of the PN-d3 molecule and the structure of the precursor and daughter ions
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Table 7: Summary of fragmentation parameters identified for all analytes examined
in this study
Analyte

Precursor
ion
(m/z)

Product ion
(m/z)

Fragmentor
voltage
(V)

Collision
energy
(eV)

PLP

248.0

149.7

45

15

PL

168.0

149.9

94

10

PMP

249.0

232.1

45

10

PM

169.0

152.0

94

10

PN

170.0

151.9

94

10

Nicotinamide

123.0

80.2

94

20

PN-d3

173.0

155.0

94

10
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3.3 Effect of changing delta values on signal response in the MS
The multiplier voltage (Delta EMV) is a parameter that significantly affect the
response in MS. In this study, different Delta values were tested by varying the voltage
from 0, 250, 500 to 750 to study its effect on the MRM signal. As can be seen from
Table 8 below, increasing the multiplier voltage, the response resulted in being
increased. However, we decided to work with Delta 0 as recommended by the Agilent
engineer to avoid damaging the instrument in the long term. Table 8 showed that Delta
0 still gave fairly high AUC which is acceptable for our analytes extraction.

3.4 The chromatographic behavior of analytes on two different columns
The chromatographic separation method was tested using two types of columns
with different dimensions and similar packing materials. The first one was Eclipse plus
C-18 with a particle size 1.8µm, an inner diameter of 2.1 and a length 50mm, and the
second one was Poroshell 120 EC-C18 with a particle size 2.7µm, an inner diameter
of 3.0 mm and a length of 100 mm. Our main reason for testing both columns was to
see which one will give most separated peaks in term of high resolution and intensity.
Both columns showed almost the same number of peaks but the elution profiles
were different. However, as we can see in Figure 10, the chromatographic profile
obtained with Poroshell column was well separated peaks with high intensity as
opposed to chromatographic profile of Eclipse plus C-18 column with separated
broadening peaks (Figure 11).

41
Table 8: Effect of increasing the Delta voltage on the area under the curve (AUC)
for each analyte tested
Analyte

.

MRM

Delta 0

Delta 250

Delta 500

Delta 750

PMP

249>232.1

414,305

469,594

955,609

1,780,831

PLP

248>149.7

63,730

207,145

403,275

770,029

PN

170>151.9 1,709,620

3,539,634

7,407,309 15,067,360

PM

169>152

686,300

1,243,534

2,700,818

PL

168>149.9 2,007,130

3,027,106

6,383,150 13,206,124

5,550,861

Nicotinamide 123>80.2

1,185,862

4,962,476 10,104,322 20,785,448

PN-d3

2,908,068

5,661,739 11,718,680 23,616,674

173>155
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Figure 10: The chromatographic profile of 8 analytes on Poroshell column

Figure 11: The chromatographic profile of 8 analytes on Eclipse plus C-18 column
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3.5 Protein precipitation and liberation of the analytes
Since the final application of our assay was the analysis of vitamins B6 and B3
in human plasma. We also wanted to determine the best method for the extraction of
these vitamins from plasma. The precipitating agent [154-155] and incubation
conditions [156] are known to generally influence the effectiveness of protein
precipitation and analyte extraction. Trichloroacetic acid (TCA) has been reported to
be effective in precipitating human plasma [154-155]. However, it is also known that
some vitamers, such PLP, is strongly bound [157-158] and requires vigorous vortexing
as well as incubation condition at 50oC for their complete release. Therefore,
incubation conditions were tested to determine which condition will give the highest
yield of our analytes from spiked simulated plasma in the present study. Three different
conditions were tested: room temperature, 50℃ and 0℃.
As can be seen in Figure 12, there was not much difference in the
chromatographic profile between ice condition and other conditions. However, the
integration of each peak of the three conditions exhibited different areas under the
curve (AUC). As can be seen in Table 9, the AUC, on ice, of PLP is 36480 which is
lower than other two conditions. However, the AUC, at room temperature, and AUC,
at 50oC, 41076, 41229 respectively are showing slight difference. The other analytes
show similar results. The significant difference between room temperature and 50℃
conditions is that the former temperature was carried out in an hour while the latter
one was carried out in 5 minutes. Therefore, performing the experiment at 50℃

(5

min) was selected as an optimum condition.
The second step was testing these three conditions on plasma sample. Table 10
shown the values of the area under the curve. It is evident that the difference between
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the two conditions can be demonstrated through the higher AUC at 50℃ than the AUC
of room temperature incubation condition in all analytes.

Figure 12: The chromatograms showing the intensity of recovered vitamins under the
three different incubation conditions
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Table 9: Area under the curve (AUC) of all analytes in simulated plasma under
different extraction conditions
0℃
(I hour)

25℃
(1 hour)

50℃
(5 min)

PMP

16,599

20,120

21,931

PLP

36,480

41,076

41,229

PN

222,146

234,575

245,534

PM

212,681

243,573

264,702

PL

230,989

277,679

275,796

Nicotinamide

240,934

313,138

352,393

Analyte

Table 10: Area under the curve (AUC) of all analytes of human plasma samples
under various conditions
25℃

50℃

(1 hour)

(5 min)

PMP

15

56

PLP

10

37

PN

420

674

PM

263

728

PL

547

1,319

Nicotinamide

1,166

2,450

PN- d3 (spiked)

159,727

186,662

Analyte
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3.6 Test of reproducibility
Analytes are sensitive to light so that all the experiments were performed in
dark and the analytes were kept in amber glassware. All stock solutions were kept at
-80℃. The amount used in every experiment was prepared daily and kept in 4℃ for
few days if needed. Therefore, reproducibility test was also done to ensure the
reproducibility of the analytes within two days and after one week.
As can be seen in Figure 13 the chromatograms after one day and in Figure 14
chromatogram after one week that there is no significant change in the intensity of the
peaks which improve the stability and reproducibility of the analytes.

Figure 13: LC-MS/MS chromatograms of 8 analytes under optimized conditions
(Day 1)
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Figure 14: LC-MS/MS chromatograms of 8 analytes under optimized conditions
(Day 2)

Figure 15: LC-MS/MS chromatograms of 8 analytes under optimized conditions
(Day 7)
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3.7 The optimized parameter for the LC-MS/MS method
Originally, our aim was to reach a method conditions to enhance the
liberation of our analytes from protein bounded components in plasma, the next goal
is to reach a separation method which can give well separated peaks with high
resolution. In Table 11 shown below, a list of the optimized conditions is represented.
After reaching our optimized conditions, they were used in the investigation of the
analyses’ recoveries. This was carried out by analysis of spiking TCA samples (Figure
16) and simulated plasma (Figure 17). The asterisk (*) in both figures refers to a peak
which could most likely be an isomer of PL as it is only shown in the extracted MRM
chromatogram of this analyte (MRM 168  149.9).
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Table 11. The optimized conditions of LC-MS/MS and the method
LC system

Agilent technologies 1260 series LC system

Column

Poroshell 120 EC-C18, (3.0 × 100 mm)

Column temperature

35℃

Autosampler
temperature

4℃

Mobile phase A

0.1% formic acid and 0.1% Heptafluorobutyric acid in
water

Mobile phase B

0.1% formic acid in Acetonitrile

Flow rate

0.4 mL/min

Injection volume

8 µL

MS conditions

6420 Triple Quad, dry gas flow 8 L/min, dry gas
temperature 325℃, nebulizer pressure 45 psi, capillary
voltage 4000 V

Gradient

Time

%A

%B

0 min

100.0%

0.0%

3.0 min

100.0%

0.0%

5.0 min

0.0%

100.0%

8.5 min

0.0%

100.0%

8.6 min

100.0%

0.0%

10.0 min

100.0%

0.0%
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Figure 16: LC-MS/MS chromatogram of all analytes in neat solution in optimized
LC-MS/MS method
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Figure 17: LC-MS/MS chromatogram of all analytes in simulated plasma solution in
optimized LC-MS/MS method

Table 12: Percentage recovery of all analytes in simulated plasma using TCA and
50℃ (5 min) incubation
Analyte

Recovery (%)

Standard deviation

PLP

121.3

19.2

PM

82.5

1.8

PL

118.0

25.6

PN

102.8

2.6

PMP

100.8

34.1

Nicotinamide

83.6

9.2

PN-d3

95.2

2.6
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3.8 Calibration curves
The calibration curves were built after preparing and running different
concentrations of all analytes and internal standard, both spiked in simulated plasma
and measuring the instrumental response of each concentration. The data shown in
Figures 17-22 of all analytes investigated in this study show a linear response in the
low range (a) and the high range (b). The square of the correlation coefficient (r2)
values were over 0.93, which means that most of the y values were not away from the
predicted line. The error bars found in certain graphs were from repeated
measurements of the same sample and are standard deviation. The lower limit of
detection (LLOD) and quantification (LLOQ) of all analytes were determined and
represented in Table 13.
The calibration curves shown in Figures 18-23 were used to interpret the
concentrations of these analytes in unknown samples, as will be discussed in the
following sections.
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Figure 18: Low range (a) and high range (b) calibration curves of PLP
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Figure 19: Low range (a) and high range (b) calibration curves of PL

55

Figure 20: Low range (a) and high range (b) calibration curves of PMP
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Figure 21: Low range (a) and high range (b) calibration curves of PM
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Figure 22: Low range (a) and high range (b) calibration curves of PN
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Figure 23: Low range (a) and high range (b) calibration curves of Nicotinamide
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Table 13: The lower limit of detection and the lower limit of quantification of
each analyte
Analyte

LLOD (pg)

LLOQ (pg)

PLP

0.66

56.0

PL

6.0

18.4

PMP

6.0

184.0

PM

18.0

56.0

PN

2.0

6.0

Nicotinamide

4,400

4,400
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3.9 Analysis of human plasma samples
3.9.1 Health patients’ plasma samples
Figure 24 show the concentrations of the analytes that were detected in unknown
human plasma samples of healthy patients. A total of fifty-seven (57) healthy human
plasma samples were analyzed in this study. It should be mentioned that PM analyte
was not detected in all samples while other analytes including PMP, PLP, PN, PL, and
nicotinamide were detected with different extents. Figure 24a shows that the average
concentration of PMP analyte in all 57 samples was around 30 nM, where patients
samples showed an even distribution around this average. The PLP analyte was
detected in the plasma samples of 14 patients only with an average concentration of
36 nM, while PLP was not detected in the samples of the remaining 43 samples, as
shown in Figure 24b. On the other hand, PN and PL analytes were detected in the
plasma samples of all 57 patients with average concentrations of 21 and 45 nM,
respectively, as shown in Figures 24c and d. Finally, nicotinamide analyte was
detected in 54 samples only with an average concentration of 850 nM, as shown in
Figure 24e. A detailed quantification of the concentrations of these analytes is shown
in Table 14.
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Figure 24: Concentrations of PMP, PL, PN, PL and Nicotinamide in healthy Emirati
population (n=57)

62
Table 14: Quantification of B3 and B6 vitamers in 57 unknown healthy plasma
samples
PMP

PLP

Sample

PN

PM

PL

Niacin

Concentration (nM)

1

42.9

n.d.

25.6

n.d.

20.3

1365.0

2

36.5

35.3

25.0

n.d.

84.3

544.9

3

21.0

n.d.

18.1

n.d.

66.8

2600.6

4

35.9

30.6

13.3

n.d.

53.8

1035.9

5

29.7

n.d.

19.2

n.d.

24.5

2492.7

6

21.4

23.5

14.9

n.d.

33.6

1338.1

7

30.7

17.6

12.7

n.d.

34.3

776.9

8

20.0

n.d.

12.3

n.d.

32.6

949.6

9

18.6

18.8

13.3

n.d.

23.8

2881.2

10

36.3

n.d.

11.3

n.d.

27.5

1138.4

11

21.6

n.d.

9.9

n.d.

31.1

3032.2

12

21.4

n.d.

15.7

n.d.

21.6

588.1

13

13.8

n.d.

17.0

n.d.

22.6

1143.8

14

17.1

38.4

9.5

n.d.

44.5

393.9

15

18.1

n.d.

22.4

n.d.

13.8

884.8

16

28.2

n.d.

23.2

n.d.

51.4

491.0

17

23.7

n.d.

18.4

n.d.

53.3

841.7

18

34.2

n.d.

22.7

n.d.

50.2

286.0

19

33.6

n.d.

16.3

n.d.

44.6

701.4

20

35.0

20.0

20.9

n.d.

58.6

1251.7

21

23.3

n.d.

30.8

n.d.

57.7

458.6

22

30.7

90.5

28.7

n.d.

130.1

n.d.

23

30.9

n.d.

21.6

n.d.

46.7

669.0

24

27.2

30.6

21.6

n.d.

53.6

1381.2

25

38.3

n.d.

19.8

n.d.

42.7

415.4

26

29.3

n.d.

19.4

n.d.

43.9

577.3

27

45.1

n.d.

19.9

n.d.

44.0

863.3

28

19.0

n.d.

21.9

n.d.

11.3

604.3

29

52.2

n.d.

18.3

n.d.

53.0

750.0

30

56.9

n.d.

13.1

n.d.

32.7

1084.5

31

82.3

38.0

17.5

n.d.

60.1

825.5

32

47.4

n.d.

21.0

n.d.

38.5

1165.4

33

51.7

n.d.

19.5

n.d.

32.2

1764.3

34

21.4

n.d.

22.0

n.d.

46.5

2390.2

35

26.6

18.8

19.4

n.d.

37.7

6005.1

36

35.9

68.9

19.1

n.d.

95.9

3620.3

37

41.2

n.d.

19.1

n.d.

32.5

830.9

38

27.4

n.d.

22.2

n.d.

42.0

965.8

39

13.8

n.d.

19.9

n.d.

42.0

1705.0
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Table 14: Quantification of B3 and B6 vitamers in 57 unknown healthy plasma
samples (continued)
PMP

PLP

Sample

PN

PM

PL

Niacin

Concentration (nM)

40

11.3

n.d.

22.8

n.d.

39.7

690.6

41

13.8

n.d.

20.3

n.d.

41.2

572.7

42

10.9

n.d.

21.7

n.d.

47.9

793.1

43

20.2

n.d.

21.0

n.d.

32.9

2303.8

44

26.6

n.d.

17.5

n.d.

48.9

n.d.

45

14.6

n.d.

19.3

n.d.

50.7

566.5

46

19.2

n.d.

22.1

n.d.

52.1

1348.9

47

35.9

37.6

24.3

n.d.

88.8

1980.1

48

15.9

n.d.

26.6

n.d.

43.3

n.d.

49

63.3

n.d.

27.1

n.d.

41.2

588.1

50

16.7

n.d.

28.2

n.d.

52.3

372.3

51

28.4

n.d.

26.0

n.d.

49.5

755.4

52

22.7

n.d.

30.1

n.d.

52.2

1429.8

53

21.4

n.d.

31.8

n.d.

49.0

302.1

54

55.9

35.6

32.4

n.d.

58.2

388.5

55

29.9

n.d.

33.2

n.d.

48.4

275.2

56

43.1

n.d.

28.5

n.d.

36.0

825.5

57

30.1

n.d.

30.3

n.d.

43.7

1143.8
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3.9.2 Obese patients’ plasma samples
Similarly, a total of fifty seven (57) unknown human plasma samples of obese
patients were also analyzed for the concentrations of the analytes in these samples.
Figure 25 shows the analysis results of five analytes (PMP, PLP, PN, PL, and
nicotinamide), while PM analyte was not detected in all plasma samples. All plasma
samples showed variable concentrations of PMP analyte with an average value of 50
nM, as shown in Figure 25a. On the other hand, the concentration of PLP analyte was
detected in the plasma samples of 8 patients only with an average value of 37 nM, as
shown in Figure 25b. The concentrations of PN and PL analytes were detected in the
plasma samples of all obese patients, with average concentrations of 21 and 61 nM,
respectively, as shown in Figures 25 c,d. Finally, the concentration of nicotinamide
analyte was detected in a total of 45 samples with an average value of 3700 nM. A
detailed quantification of the concentrations of these analytes is shown in Table 15.
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Figure 25: Concentrations of PMP, PL, PN, PL and Nicotinamide in obese Emirati
population (n=57)
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Table 15: Quantification of B3 and B6 vitamers in 57 unknown obese plasma
samples
PMP

PLP

Sample

PN

PM

PL

Niacin

Concentration (nM)

1

12.0

n.d.

24.7

n.d.

51.5

5471.0

2

34.4

n.d.

20.8

n.d.

n.d.

1823.7

3

13.6

n.d.

21.7

n.d.

48.4

1348.9

4

n.d.

n.d.

39.5

n.d.

n.d.

n.d.

5

64.3

26.2

20.9

n.d.

114.9

2314.6

6

27.8

n.d.

20.1

n.d.

58.3

1246.3

7

69.1

n.d.

21.0

n.d.

46.4

3118.6

8

14.2

n.d.

26.3

n.d.

62.2

1516.1

9

79.2

29.8

25.8

n.d.

74.7

10

37.1

n.d.

23.8

n.d.

57.0

2514.3
n.d.

11

36.1

30.2

27.2

n.d.

41.7

n.d.

12

28.7

n.d.

24.5

n.d.

45.4

n.d.

13

46.4

n.d.

23.4

n.d.

57.9

n.d.

14

15.0

n.d.

23.6

n.d.

n.d.

2044.9

15

14.4

n.d.

30.8

n.d.

n.d.

2217.5

16

24.1

n.d.

25.8

n.d.

n.d.

2854.2

17

31.3

36.8

21.2

n.d.

70.0

3177.9

18

77.9

n.d.

35.3

n.d.

63.1

2082.6

19

15.9

69.3

28.7

n.d.

95.1

3679.7

20

33.2

n.d.

24.4

n.d.

41.2

3323.6

21

20.6

n.d.

26.1

n.d.

57.6

n.d.

22

24.3

61.5

21.3

n.d.

97.3

1818.3

23

22.5

n.d.

20.3

n.d.

41.4

5956.5

24

18.6

n.d.

21.1

n.d.

41.1

6167.0

25

59.8

n.d.

28.0

n.d.

40.7

2271.5

26

42.9

n.d.

29.1

n.d.

86.2

1645.6

27

18.3

n.d.

22.4

n.d.

41.5

4526.8

28

33.2

n.d.

25.0

n.d.

40.0

3275.0

29

21.2

n.d.

23.4

n.d.

70.1

4402.7

30

16.1

n.d.

20.6

n.d.

54.3

3258.8

31

77.3

n.d.

12.6

n.d.

56.7

5287.5

32

32.4

22.7

11.8

n.d.

62.6

8810.7

33

94.8

n.d.

14.3

n.d.

59.0

2401.0

34

86.0

n.d.

14.8

n.d.

35.8

1494.5

35

38.8

n.d.

24.3

n.d.

93.9

5406.2

36

243.9

n.d.

18.0

n.d.

63.6

9625.4

37

138.3

n.d.

20.7

n.d.

65.3

11303.4

38

44.3

n.d.

12.1

n.d.

76.3

5109.5

39

100.6

n.d.

12.0

n.d.

58.3

4337.9
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Table 15: Quantification of B3 and B6 vitamers in 57 unknown obese plasma
samples (continued)
PMP

PLP

Sample

PN

PM

PL

Niacin

Concentration (nM)

40

95.4

n.d.

6.7

n.d.

75.6

3345.2

41

101.0

42

47.8

n.d.

n.d.

n.d.

58.3

4105.9

n.d.

20.7

n.d.

n.d.

n.d.

43

25.6

n.d.

17.6

n.d.

n.d.

3998.0

44

34.8

n.d.

21.8

n.d.

n.d.

3064.6

45

90.9

n.d.

16.4

n.d.

n.d.

3933.3

46

168.2

27.8

21.3

n.d.

60.6

1386.6

47

17.5

n.d.

19.2

n.d.

n.d.

7181.3

48

27.2

n.d.

12.7

n.d.

25.2

10693.7

49

191.9

n.d.

7.7

n.d.

n.d.

372.3

50

65.3

n.d.

13.5

n.d.

n.d.

2832.6

51

53.8

n.d.

15.4

n.d.

n.d.

2498.1

52

19.8

n.d.

14.0

n.d.

n.d.

3884.7

53

39.0

n.d.

7.8

n.d.

n.d.

3965.6

54

87.2

n.d.

12.9

n.d.

n.d.

933.4

55

26.8

n.d.

9.5

n.d.

n.d.

2476.5

56

54.6

n.d.

11.4

n.d.

n.d.

2633.0

57

23.7

n.d.

8.8

n.d.

n.d.

3539.4
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A comparative analysis was also carried out between the concentrations of the
analytes found in the plasma samples of healthy versus obese patients. We also
compared our data with a representative data set of vitamin concentrations in healthy
human plasma previously published by Redeuil et al in 2015 [119], Table 16.
Compared with an average normal concentration of 4.9 nM PMP (as published by
Redeuil et al), we found higher PMP concentration in our healthy and obese Emirati
population, with values of 30.2 and 53.2 nM of PMP, respectively. A similar pattern
was also observed for nicotinamide, where our values in healthy and obese plasma
samples (1206.5 and 3733.5 nM, respectively), were higher than the published average
value of 274.4 nM. On the other hand, the average concentrations of the PLP, PN and
PL were found to be lower in the plasma samples of both healthy and obese patients
as compared with published concentrations. Hence, it appears that both healthy and
obese Emirati plasma samples, as analyzed in the current study, showed high
concentrations of PMP and nicotinamide and lower concentration than published
values of PM, PLP, PN and PL vitamers. It is also worth noting that obese Emirati
patients showed significantly higher average concentrations of PMP (p value = 0.002),
PL (p value = 0.0006) and nicotinamide (p value < 0.0001) than healthy patients, as
judged by student’s t-test analysis, Figure 25. Plasma concentrations of B6 vitamers
PLP and PN were not significantly different between healthy and obese Emirati
populations (Figure 25b and c). These interesting differences could be due to various
factors, such as vitamin supplementation, higher caloric and food intake, other
metabolic imbalances, single nucleotide polymorphisms or genetic differences. The
exact nature and cause of this interesting finding will be carefully examined in future
studies involving a larger population size. Nevertheless, this initial pilot study points
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to the need and value of studying plasma concentrations of vitamers in metabolically
distinct populations.

Table 16: Comparison between the concentrations of all analytes in the plasma
samples of healthy and obese Emirati population
Analyte
(nM)
PMP
PLP
PN
PM
PL
Nicotinamide

Healthy Plasma
Obese Plasma
Average
Max
Min
Average
Max
30.2
82.3
10.9
53.2
243.9
36.0
90.5
n.d.
38.0
69.3
21.0
33.2
9.5
20.1
39.5
Not detected
45.8
130.1
11.3
60.2
114.9
1206.5 6005.1 275.2
3733.5 11303.4

Min
12.0
n.d.
6.7
n.d.
372.3

Table 17: Comparison between the concentrations of all analytes in the
plasma samples of healthy population and those mentioned in the literature
Analyte
(nM)
PMP
PLP
PN
PM
PL
Nicotinamide

Healthy Emirati Plasma
Average
Max
Min
30.2
82.3
10.9
36.0
90.5
n.d.
21.0
33.2
9.5
Not detected
45.8
130.1
11.3
1206.5 6005.1 275.2

US Population [119]
Average
Max
Min
4.9
7.6
2.1
92.1
163.3
20.9
142.8
285.4
0.2
4.1
7.7
0.4
118.4
233.5
3.2
274.4
479.6
69.1

European Population
Average
Max
Not detected
34.4
102.3
Not detected
Not detected
9.9
28.2
Not included

[159]
Min
17.0

5.7
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Figure 26: Comparative analysis of various B6 vitamers and B3 (nicotinamide) in
healthy versus obese Emirati population
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A comparative analysis was also carried out between the concentrations of
the analytes found in the plasma samples of healthy and obese Emirati populations.
Table 16 shows that PMP concentration in the obese Emirati population was 53.2 nM,
which is higher than that in the plasma samples of healthy Emirati population; 30.2
nM. The average concentration of PL (60.2 nM) and nicotinamide (3,733.5 nM) in
obese population were both higher than their respective values detected in the healthy
populations samples; 45.8 nM and 1,206.5 nM, respectively. It should be mentioned
that PM was not detected in the plasma samples of both populations. It is also worth
noting that obese Emirati population showed significantly higher average
concentrations of PMP (p value = 0.002), PL (p value = 0.0006), and nicotinamide (p
value < 0.0001) than healthy population, as judged by student t-test analysis. This is
shown in Figure 26. Plasma concentration of B6 vitamers; PLP and PN were not
significantly different between healthy and obese Emirati population (Figure 26b and
c). Since synthetic vitamins were used to fortify food and as supplements in the late
1930s, vitamin intake has significantly increased. The vitamin paradox in obesity may
be a reflection of excess vitamin intake rather than vitamin deficiency given that there
is a correlation between high vitamin intake and increased obesity [160]. These
interesting differences could be related to various factors, such as vitamin
supplementation, higher caloric and food intake, other metabolic imbalance, and single
nucleotide polymorphisms or genetic differences. The exact nature and cause of these
findings will be carefully examined in future studies involving a larger population size.
Additionally, this data could also be correlated with gender, body weight, as well as
other plasma parameters, such as complete blood count, HbA1c, interleukins, liver
function enzymes, etc. Nevertheless, this initial pilot study points to the need and value
of studying plasma concentration of vitamers in metabolically distinct populations.
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We also compared our data of healthy population with two representative data
sets of vitamin concentrations in healthy human plasma previously published by
Redeuil et al. in 2015 [119], and Midttun et al. in 2005 [159]. Table 17 shows higher
PMP concentration in our healthy Emirati population, with value of 30.2 nM. A similar
pattern was also observed for nicotinamide, where our value in healthy plasma sample
was 1206.5 nM. These values were higher than their respective concentrations in the
samples of US population. On the other hand, the average concentration of PLP, PN,
and PL were found to be lower in the plasma samples of our healthy population as
compared with those in the US population. It should be mentioned that PLP and PL
vitamers were only detected in the plasma samples of European healthy population.
The data shown in Table 17 indicate that the concentration of PL vitamer in the
European population samples were one forth that of our healthy Emirati population,
whereas the concentration of PLP was similar in both cases. It is also important to
mention that nicotinamide was not studied in the work of Midttun et al, which explains
why it was not compared with our results for this vitamers.
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Chapter 4: Conclusions
In summary, the results presented here summarize the development of a rapid,
sensitive and robust LC-MS/MS based assay for the simultaneous quantification of six
different vitamers in human plasma. The method involves a simple, single step
precipitation-based extraction of vitamins from human plasma for subsequent analysis
by MRM-based LC-MS/MS method. This technique was subsequently used to analyze
plasma samples taken from 57 healthy and 57 obese Emirati patients from a local
hospital. Our results show that B6 vitamers as well as nicotinamide concentrations in
healthy Emirati population are significantly different than those published in literature
for Western populations. Additionally, we observed significant differences in plasma
vitamin B6 and B3 concentrations between healthy and obese Emirati samples. The
reasons behind this interesting finding will be the focus of future studies. It will also
be interesting to see if the increased levels of B6 vitamers and vitamin B3 are
correlated with any physiological imbalances or disease states in obese patients.
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